Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) said its aminolevulinic acid hydrochloride powder for oral solution was accepted for Chinese regulatory review, according to a Hong Kong bourse filing Thursday.
The product is used to help surgeons visualize high-grade glioma tissue during surgery.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.